Avalyn nebulized antifibrotic medications are being studied in this clinical trial. These medications are designed to help manage and treat lung conditions by reducing the formation of scar tissue in the lungs. The goal is to improve breathing and lung function over time. Participants in the trial will use these medications in a form that is inhaled through a nebulizer, which turns the medication into a mist that can be easily breathed into the lungs. This method allows the medication to directly reach the lungs, where it can work to prevent or slow down the scarring process.

Progressive Pulmonary Fibrosis – Progressive pulmonary fibrosis is a condition characterized by the gradual scarring of lung tissue, which leads to a decline in lung function over time. The scarring, or fibrosis, makes it increasingly difficult for the lungs to transport oxygen into the bloodstream. As the disease progresses, individuals may experience worsening shortness of breath, a persistent dry cough, and fatigue. The progression of fibrosis can vary among individuals, with some experiencing a rapid decline in lung function. Over time, the reduced lung capacity can significantly impact daily activities and quality of life. The exact cause of the fibrosis is often unknown, and it can occur as part of other lung diseases.

Idiopathic Pulmonary Fibrosis – Idiopathic pulmonary fibrosis is a specific type of chronic lung disease where the lung tissue becomes thickened, stiff, and scarred without a known cause. This scarring, known as fibrosis, progressively worsens, leading to a decline in lung function. Individuals with this condition often experience symptoms such as shortness of breath, especially during physical activity, and a persistent dry cough. As the disease advances, the ability to breathe deeply and efficiently is compromised, affecting oxygen levels in the blood. The progression of idiopathic pulmonary fibrosis can vary, with some individuals experiencing a slow decline and others a more rapid progression. The term “idiopathic” indicates that the cause of the fibrosis is unknown.